John C. Jacobs - Jan 23, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President and CEO, Director
Signature
/s/ Mark J. Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Jan 23, 2024
Transactions value $
-$170,796
Form type
4
Date filed
1/25/2024, 05:00 PM
Previous filing
Jan 25, 2023
Next filing
Mar 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +83.2K 83.2K Jan 23, 2024 Direct F1
transaction NVAX Common Stock Tax liability -$171K -40.1K -48.19% $4.26 43.1K Jan 23, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -83.2K -33.33% $0.00 166K Jan 23, 2024 Common Stock 83.2K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date.